Full metadata record
DC FieldValueLanguage
dc.creatorMorbelli, S. (Silvia)-
dc.creatorEsposito, G. (Giuseppe)-
dc.creatorArbizu, J. (Javier)-
dc.creatorBarthel, H. (Henryk)-
dc.creatorBoellaard, R. (Ronald)-
dc.creatorBohnen, N. (Nico)-
dc.creatorBrooks, D.J. (David J.)-
dc.creatorDarcourt, J. (Jacques)-
dc.creatorDickson, J.C. (John C.)-
dc.creatorDouglas, D. (David)-
dc.creatorDrzezga, A. (Alexander)-
dc.creatorDubroff, J. (Jacob)-
dc.creatorEkmekcioglu, O. (Ozgul)-
dc.creatorGaribotto, V. (Valentina)-
dc.creatorHerscovitch, P. (Peter)-
dc.creatorKuo, P. (Phillip)-
dc.creatorLammertsma, A. (Adriaan)-
dc.creatorPappata, S. (Sabina)-
dc.creatorPeñuelas-Sanchez, I. (Ivan)-
dc.creatorSeibyl, J. (John)-
dc.creatorSemah, F. (Franck)-
dc.creatorTossici-Bolt, L. (Livia)-
dc.creatorVan-de-Giessen, E. (Elsmarieke)-
dc.creatorVan-Laere, K. (Koen)-
dc.creatorVarrone, A. (Andrea)-
dc.creatorWanner, M. (Michele)-
dc.creatorZubal, G. (George)-
dc.creatorLaw, I. (Ian)-
dc.identifier.citationMorbelli, S. (Silvia); Esposito, G. (Giuseppe); Arbizu, J. (Javier); et al. "EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0". European Journal of Nuclear Medicine and Molecular Imaging. 47, 2020, 1885 - 1912es_ES
dc.description.abstractPurpose This joint practice guideline or procedure standard was developed collaboratively by the European Association of Nuclear Medicine (EANM) and the Society of Nuclear Medicine and Molecular Imaging (SNMMI). The goal of this guideline is to assist nuclear medicine practitioners in recommending, performing, interpreting, and reporting the results of dopaminergic imaging in parkinsonian syndromes. Methods Currently nuclear medicine investigations can assess both presynaptic and postsynaptic function of dopaminergic synapses. To date both EANM and SNMMI have published procedural guidelines for dopamine transporter imaging with single photon emission computed tomography (SPECT) (in 2009 and 2011, respectively). An EANM guideline for D2 SPECT imaging is also available (2009). Since the publication of these previous guidelines, new lines of evidence have been made available on semiquantification, harmonization, comparison with normal datasets, and longitudinal analyses of dopamine transporter imaging with SPECT. Similarly, details on acquisition protocols and simplified quantification methods are now available for dopamine transporter imaging with PET, including recently developed fluorinated tracers. Finally, [18F]fluorodopa PET is now used in some centers for the differential diagnosis of parkinsonism, although procedural guidelines aiming to define standard procedures for [18F]fluorodopa imaging in this setting are still lacking. Conclusion All these emerging issues are addressed in the present procedural guidelines for dopaminergic imaging in parkinsonian syndromes.es_ES
dc.description.sponsorshipSilvia Morbelli has received speaker honoraria from GE Healthcare and Eli-Lilly; Javier Arbizu has received research grants from Lilly-Avid, General Electric Healthcare, and Piramal and speaker honoraria from Biogen, Araclon Biotech-Grifols, Bayer, and Novartis; Ronald Boellaard has provided data analysis service for Bristol Meyers Squibb, Rodin, and Roche and is a scientific advisor for EARL; Nico Bohnen has received research support from the NIH, Department of Veteran Affairs, the Michael J. Fox Foundation, Eisai, Axovant Sciences, and Chase Pharmaceuticals; David Brooks was consultant for GE Healthcare and Biogen; John C. Dickson was consultant for GE Healthcare, Bioclinica, and Biogen; Alexander Drzezga has received speaker honoraria from Siemens Healthineers, Sanofi, and Henning and received research support from AVID/Lilly, Life Molecular Imaging, GE Healthcare, and Siemens Healthineers; Jacob Dubroff received speaker honoraria from IBA; Peter Herscovitch is a member of Medical Imaging Drug Advisory Committee of US Food and Drug Administration; John Seibyl is consultant for Invicro, Biogen, Roche, Life Molecular Imaging, and LikeMinds and has equity holding of Invicro; K. Van Laere has performed consultancy services and contract research, through KU Leuven, for GE Healthcare, Merck, Janssen Pharmaceuticals, UCB, Syndesi Therapeutics, and Eikonizo; Ian Law has received speaker honoraria from Siemens Healthcare. The other authors declare no conflict of interest.es_ES
dc.subjectParkinsonian syndromeses_ES
dc.titleEANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0es_ES
dc.description.noteThis. article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.es_ES
dc.editorial.noteSpringer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.es_ES
dadun.citation.publicationNameEuropean Journal of Nuclear Medicine and Molecular Imaginges_ES

Files in This Item:
699.65 kB
Adobe PDF

Statistics and impact

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.